MARKET

ALDX

ALDX

Aldeyra Therapeu
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.960
-0.030
-0.75%
Opening 10:45 07/01 EDT
OPEN
3.970
PREV CLOSE
3.990
HIGH
4.070
LOW
3.910
VOLUME
91.17K
TURNOVER
238.41K
52 WEEK HIGH
11.45
52 WEEK LOW
2.355
MARKET CAP
230.87M
P/E (TTM)
-3.5789
1D
5D
1M
3M
1Y
5Y
Trade Alert: The CEO, President & Director Of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX), Todd Brady, Has Just Spent US$60k Buying 2.4% More Shares
Even if it's not a huge purchase, we think it was good to see that Todd Brady, the CEO, President & Director of Aldeyra...
Simply Wall St. · 3d ago
Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Simply Wall St. · 06/21 15:01
Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
LEXINGTON, Mass., June 09, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chie...
Business Wire · 06/09 12:00
--Oppenheimer Adjusts Aldeyra Therapeutics Price Target to $11 From $10, Maintains Outperform Rating
MT Newswires · 06/09 10:11
Citigroup Adjusts Aldeyra Therapeutics' Price Target to $26 From $21, Reiterates Buy Rating
MT Newswires · 06/09 07:28
Why Aldeyra Therapeutics' Shares Are Soaring Today?
Benzinga · 06/08 13:40
Aldeyra stock soars as dry eye disease drug meets main goal in late stage study
Aldeyra Therapeutics (NASDAQ:ALDX) stock rose ~14% premarket June 8 after the company said a phase 3 trial, dubbed TRANQUILITY-2, of dry eye disease therapy reproxalap met its main goals. In
Seekingalpha · 06/08 12:00
Aldeyra Therapeutics Achieves Primary Endpoint In Phase 3 TRANQUILITY‑2 Trial In Dry Eye Disease And Says Intends To Submit New Drug Application For Symptoms And Three Sign Endpoints Of Dry Eye Disease
Reproxalap Statistically Superior to Vehicle for Both Prespecified Primary Endpoints of Schirmer Test (p=0.0001) and ≥10 mm Schirmer Test Responder Proportions (p<0.0001) TRANQUILITY-2 Results May Allow for the
Benzinga · 06/08 11:04
More
No Data
Learn about the latest financial forecast of ALDX. Analyze the recent business situations of Aldeyra Therapeu through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

62.50%Strong Buy
37.50%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ALDX stock price target is 19.88 with a high estimate of 30.00 and a low estimate of 11.00.
High30.00
Average19.88
Low11.00
Current 3.800
EPS
Actual
Estimate
-0.26-0.19-0.13-0.06
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 146
Institutional Holdings: 41.64M
% Owned: 71.41%
Shares Outstanding: 58.30M
TypeInstitutionsShares
Increased
34
7.40M
New
17
2.60M
Decreased
37
5.96M
Sold Out
21
1.92M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.10%
Pharmaceuticals & Medical Research
+0.97%
Key Executives
Non-Executive Chairman/Independent Director
Richard Douglas
President/Chief Executive Officer/Director
Todd Brady
Chief Financial Officer/Vice President - Finance/Treasurer
Bruce Greenberg
Other
Stephen Machatha
Independent Director
Ben Bronstein
Independent Director
Martin Joyce
Independent Director
Nancy Millerrich
Independent Director
Gary Phillips
Independent Director
Neal Walker
No Data
No Data
About ALDX
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in developing immune-modulating therapies to treat ocular and systemic diseases. The Company's lead product candidate, reproxalap, is a treatment in late-stage development for dry eye disease (DED) and allergic conjunctivitis (AC). It has additional product candidates in development for proliferative vitreoretinopathy (PVR), primary vitreoretinal lymphoma (PVRL) and other retinal diseases, autoimmune disease, and cancer. The Company's product development pipeline is focused on immune-mediated ocular diseases and select systemic diseases and encompasses three biological mechanisms of action: reactive aldehyde species (RASP) inhibition, dihydrofolate reductase (DHFR) inhibition, and protein chaperome (CHP) inhibition. The immunological activity of its product candidates generally leads to diminished levels of pathological inflammation via down-regulation of immune cell activation or proliferation.

Webull offers kinds of Aldeyra Therapeutics Inc stock information, including NASDAQ:ALDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALDX stock methods without spending real money on the virtual paper trading platform.